Promising drug duo targets Hard-to-Treat HER2 cancers
NCT ID NCT07243938
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, zanidatamab and tislelizumab, combined with standard chemo or radiation for people with HER2-positive stomach or colorectal cancers. About 70 adults aged 18-75 will receive the treatment to see if it shrinks tumors and controls the disease. The goal is to improve outcomes while monitoring side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can precision protons spare rectal cancer patients from harsh side effects?
- Could a single drug replace surgery for rectal cancer?
- Can a gut bacteria transplant help immunotherapy wipe out rectal cancer before surgery?
- Can adding chemo after radiation help older adults with rectal cancer avoid surgery?
- Can a common muscle relaxant make radiation deadlier for rectal cancer?